Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05091567
Title A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer (IMforte)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

lung small cell carcinoma

Therapies

Atezolizumab + Carboplatin + Etoposide

Atezolizumab + Carboplatin + Etoposide + Lurbinectedin

Age Groups: adult | senior
Covered Countries USA | ITA | ESP | DEU | BEL


No variant requirements are available.